SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
VERA reported Q3 2026 results. The stock moved -1.2% on the print.
VERAearnings

Earnings reactions, page 6

Vera Therapeutics, Inc. (VERA) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Net product revenue was $10,277 thousand for the three months ended September 30, 2026, compared to $0 for the prior year period.
  • Net loss was $93,711 thousand, or $1.30 per share, for the third quarter of 2026, compared to a net loss of $80,293 thousand, or $1.26 per share, for the third quarter of 2025.
  • Research and development expenses were $41,253 thousand for the three months ended September 30, 2026, compared with $56,473 thousand in the prior-year quarter.
  • Selling, general and administrative expenses were $61,430 thousand for the third quarter of 2026, compared with $27,459 thousand during the prior year period.
  • Cash, cash equivalents, and marketable securities totaled $384,042 thousand as of September 30, 2026.

Price and volatility reaction

The stock moved -1.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +1.4 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release30.142026-11-05
Close after release29.7852026-11-06
Realised move-1.2%close to close
30d ATM IV change+1.4 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →